More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026
BioArctic's partner Eisai presented data from the real-world LEADER study at AAIC 2026, showing that 82.5% of early Alzheimer's patients treated with Leqembi remained stable or improved over an average of 17 months. The retrospective analysis of 432 patients demonstrated consistent efficacy across diverse demographics and an ARIA safety profile that aligns with the FDA-approved label.
Key figures
- Drug Name
- Leqembi (lecanemab)
- Study interim patients
- 432
- Arria overall incidence
- 12.3%
- Patients stable percent
- 75.9%
- Patients improved percent
- 6.6%
- Treatment duration avg months
- 17
- Patients stable or improved percent
- 82.5%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.